New England Journal of Medicine

The New England Journal of Medicine (NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It describes itself as the oldest continuously published medical journal in the world. The journal publishes editorials, papers on original research, review articles, correspondence, and case reports, and has a special section called "Images in Clinical Medicine". In September 1811, John Collins Warren, a Boston physician, along with James Jackson, submitted a formal prospectus to establish the New England Journal of Medicine and Surgery and Collateral Branches of Science as a medical and philosophical journal. Subsequently, the first issue of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science was published in January 1812. The journal was published quarterly. On April 29, 1823, another publication, the Boston Medical Intelligencer, appeared under the stewardship of Jerome V.C. Smith. The Intelligencer ran into financial troubles in the spring of 1827, and the editors of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science purchased it in February 1828

Publisher
Massachusetts Medical Society
Country
United States
History
The New England Journal of Medicine and Surgery (1812–1826);
The New England Medical Review and Journal (1827);
The Boston Medical and Surgical Journal (1828–1927);
The New England Journal of Medicine (1928–present)
Impact factor
53.484 (2010)
Some content from Wikipedia, licensed under CC BY-SA

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Oct 23, 2014
popularity not rated yet | comments 0

Immune therapy induces remission for many with ALL

(HealthDay)—An experimental immune-system therapy can often lead to complete remission in advanced acute lymphoblastic leukemia (ALL) patients who have run out of other options, according to research published ...

Oct 16, 2014
popularity not rated yet | comments 0

Data sharing in pharmaceutical industry shows progress

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Oct 16, 2014
popularity not rated yet | comments 0

'The FDA, e-cigarettes, and the demise of combusted tobacco'

The popularity of E-cigarettes could lead to the "demise" of cigarette smoking and save thousands of lives, but not until they are proven safe and are regulated by the U.S. Food and Drug Administration (FDA). That's the message ...

Oct 15, 2014
popularity 4.3 / 5 (3) | comments 0